TABLE 2.
Delivery methods and neonatal background
| Group | Case | Delivery | Adaptation | Delivery weeks | Sex | Weight (g) | Weight (percentile) | APGAR (1 min) | APGAR (5 min) | pH | BE | Placental weight (g) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAS/IMB | 1 | VD | 38 | F | 3008 | 60.6 | 9 | 10 | — | — | 478 | |
| 2 | VD | 38 | M | 2776 | 33.8 | 10 | 10 | 7.33 | −5.5 | 470 | ||
| 3 | CS | Previous CS | 37 | F | 2296 | 9.2 | 10 | 10 | 7.29 | −4.2 | 479 | |
| 4 | CS | Placental abruption | 36 | F | 2474 | 38.8 | 2 | 3 | 7.26 | −6.7 | 501 | |
| 5 | VD | 40 | F | 2510 | 4.9 | 9 | 9 | 7.41 | −2.0 | 412 | ||
| 6 | CS | Previous CS | 38 | F | 2739 | 37.1 | 8 | 9 | 7.37 | 0.7 | 470 | |
| 7 | VD | 41 | F | 3300 | 72.1 | 9 | 9 | 7.33 | −1.2 | 610 | ||
| 8 | CS | Previous CS | 38 | M | 3244 | 81.0 | 9 | 10 | — | — | 630 | |
| non‐CAS/IMB | 1 | VD | 40 | M | 3450 | 73.6 | 9 | 10 | 7.24 | −8.0 | 623 | |
| 2 | VD | 40 | F | 4234 | 100 | 8 | 9 | 7.35 | −1.9 | 720 | ||
| 3 | CS | COVID‐19 | 35 | F | 2830 | 96.3 | 5 | 8 | 7.33 | −3.6 | 650 | |
| 4 | VD | 40 | F | 2905 | 27.6 | 8 | 9 | 7.32 | −3.2 | 560 | ||
| 5 | VD | 40 | F | 3148 | 39.7 | 9 | 10 | 7.30 | −6.8 | 630 | ||
| 6 | CS | COVID‐19 | 36 | M | 2672 | 76.4 | 8 | 9 | 7.27 | −7.0 | 610 | |
| 7 | VD | 40 | M | 3168 | 58.7 | 9 | 10 | 7.32 | −6.0 | 696 | ||
| 8 | VD | 40 | M | 3350 | 77.4 | 10 | 10 | 7.36 | −2.9 | 517 | ||
| 9 | VD | 38 | F | 3082 | 68 | 9 | 9 | 7.22 | −8.4 | 554 | ||
| 10 | VD | 39 | F | 2664 | 18.6 | 9 | 9 | 7.34 | −1.4 | 542 |
Abbreviations: —, Specimens not collected; APGAR, APGAR score; BE, base excess; CAS/IMB, casirivimab and imdevimab; CS, cesarean section; F, female; M, male; VD, vaginal delivery.